Publications by authors named "Sheena Maltby"
Antibody responses to SARS-CoV-2 vaccines vary for reasons that remain poorly understood. A range of sociodemographic, behavioural, clinical, pharmacologic and nutritional factors could explain these differences. To investigate this hypothesis, we tested for presence of combined IgG, IgA and IgM (IgGAM) anti-Spike antibodies before and after 2 doses of ChAdOx1 nCoV-19 (ChAdOx1, AstraZeneca) or BNT162b2 (Pfizer-BioNTech) in UK adults participating in a population-based longitudinal study who received their first dose of vaccine between December 2020 and July 2021.
View Article and Find Full Text PDFObjective: To determine the effect of population level implementation of a test-and-treat approach to correction of suboptimal vitamin D status (25-hydroxyvitamin D (25(OH)D) <75 nmol/L) on risk of all cause acute respiratory tract infection and covid 19.
Design: Phase 3 open label randomised controlled trial.
Setting: United Kingdom.
Article Synopsis
- A prospective study in the UK analyzed factors influencing pre-vaccination antibody responses to SARS-CoV-2 among 11,130 vaccine-naive adults, tracking data collected via online questionnaires and blood tests.* -
- Of the participants, 15.2% tested positive for antibodies, with increased seropositivity linked to frontline healthcare jobs, international travel, high shopping frequency, higher BMI, South Asian ethnicity, and significant alcohol consumption.* -
- Among those who were seropositive, higher anti-Spike antibody levels were associated with similar risk factors and behaviors, emphasizing the role of BMI, ethnicity, occupation, travel, and shopping habits in antibody response.*